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Stroke is a major cause of adult disability. The 2012 Cochrane Review of SSRIs for 
stroke recovery demonstrated positive effects on recovery. We updated this review 
in 2019 because a large trial of fluoxetine for stroke recovery (Fluoxetine or Control 
Under Supervision, FOCUS) was published in December 2018.  
Objectives 
To determine if SSRIs are more effective than placebo or usual care at improving 
outcomes in people less than 12 months post‐stroke, and to determine associations 
with adverse effects.  
Search methods 
We searched several electronic databases up to July 2018, trials registers and grey 
literature.  
Selection criteria 
We selected all randomized controlled trials (RCTs) of any SSRI treatment versus no 
usual care or placebo recruiting patients who had had a stroke in the previous year. 
Trials had to collect data on at least one of our primary (disability score or 
independence) or secondary outcomes (impairments, depression, anxiety, quality of 
life, fatigue, healthcare cost, death, adverse events and leaving the trial early).  
Data collection and analysis 
Two review authors independently extracted data and assessed risk of bias. We 
calculated standardised mean differences (SMDs), and risk ratios (RRs) as 
appropriate. We restricted the primary analysis to studies at low risk of bias.  
Main results 
We identified a total of 63 eligible trials recruiting 9168 participants. About half the 
trials required participants to have depression to enter the trial. The duration, drug, 
and dose varied between trials. Meta‐analysis of the three trials at low risk of bias 
found no effect of SSRI on disability score (SMD −0.01; 95% CI −0.09 to 0.06; P = 
0.75; 2 studies, 2829 participants) or independence (RR 1.00; 95% CI 0.91 to 1.09; 
P = 0.99; 3 studies, 3249 participants) (see Figure). We downgraded both these 























    
    
    
    
    
    
    
    





Figure: Forest plot of the outcome independence; comparing SSRIs with usual care 
or placebo. CI indicates confidence interval. 
SSRIs reduced the depression scores but increased gastrointestinal side effects. 
When all trials were included irrespective of risk of bias, SSRIs reduced disability 
scores but not dependence.  
Authors' conclusions and implication 
There is no reliable evidence that SSRIs should be used routinely to promote 
recovery after stroke.  
Implications for research  
This review will be updated again when two large ongoing trials are published in 
2020. 
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This paper is based on a Cochrane Review published in The Cochrane Library 2019, 
Issue 11 (see www.thecochranelibrary.com for information). Cochrane Reviews are 
regularly updated as new evidence emerges and in response to feedback, and The 
Cochrane Library should be consulted for the most recent version of the review.  
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Figure: Forest plot of the outcome independence; comparing SSRIs with usual care 
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